Proteomic Risk Score Predicts Kidney Disease Progression in APOL1 High-Risk Genotypes

Researchers have developed a proteomic risk score that can predict the progression of kidney disease in individuals with high-risk APOL1 (apolipoprotein L1) genotypes. Published in Nature Medicine on April 15, 2026, the study introduces a tool designed to identify those most likely to experience rapid decline toward kidney failure years before clinical symptoms manifest.

The APOL1 high-risk genotypes are significantly enriched in individuals of African ancestry. While these genetic markers indicate a predisposition to kidney issues, the presence of the genotype does not guarantee the development of the disease. This new tool, known as the APOL1 Proteomic Risk Score (APRS), aims to bridge the gap between genetic susceptibility and actual clinical outcomes.

Development and Accuracy of the APRS

The APRS was derived by profiling the plasma proteomes of 851 participants of African ancestry from the Penn Medicine BioBank. These participants all carried APOL1 high-risk genotypes and had a preserved estimated glomerular filtration rate (eGFR) of 60 ml min−1 1.73 m−2 or higher.

Using elastic net Cox regression adjusted for sex, age, albuminuria and eGFR, researchers identified a specific set of nine proteins to create the risk score. The score predicts a composite outcome consisting of death, kidney failure, or an eGFR decline of 40% or more.

The APRS demonstrated a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%. This performance outperformed existing tools, including polygenic risk scores and the Kidney Failure Risk Equation, which achieved a tAUC of 66.1%.

The study found a stark difference in 10-year event rates across risk quintiles, ranging from 3.3% in the lowest risk group to 62.5% in the highest risk group. The accuracy of the score was further confirmed through external validation in the UK Biobank and Atherosclerosis Risk in Communities cohorts, where tAUC values remained robust between 82% and 85%.

Biological Plausibility and Clinical Impact

The proteins used to calculate the APRS correlate with tubular injury pathways and kidney tissue fibrosis. This correlation provides biological plausibility for the score’s ability to predict disease progression.

The ability to identify high-risk individuals early is intended to shift medical intervention from reactive treatment to proactive, personalized prevention. By identifying who is most likely to experience rapid organ failure, the APRS provides a precision medicine framework that may help reduce healthcare disparities for Black Americans and other populations of African descent.

Kidney failure, also referred to as end-stage kidney disease (ESKD), is a life-threatening condition. Survival for those with ESKD requires kidney transplantation or dialysis, both of which impose significant global and societal costs.

Addressing Missing Heritability

For years, the medical community has faced the challenge of missing heritability regarding APOL1-mediated kidney disease. This refers to the observation that some individuals with high-risk genes remain healthy throughout their lives, while others experience rapid progression to failure.

The APRS addresses this by moving beyond genetic markers alone. By analyzing protein levels in the blood, clinicians may be able to determine not just if a patient has a genetic risk, but if and when that risk will translate into actual organ failure.

This scalable approach may also accelerate the development of targeted APOL1 therapies, potentially allowing for interventions to begin long before the onset of clinical symptoms.